Clinical trials: Breast Cancer (Early Breast Cancer)
Early-stage Breast Cancer, Invasive Ductal Carcinoma of Female Breast
Radiation After No Axillary Nodal Sampling
This is a single arm, pilot, prospective study to evaluate the safety of partial breast irradiation in women who undergo breast conserving surgery without sentinel lymph node biopsy (SLNB) or axillary lymph node dissection…
- Trial name
- RADIANS (NCT07723209)
- Testing
- Partial Breast Irradiation (PBI)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- NYU Langone Health
Omitting Sentinel Lymph Node Biopsy in Early-stage Breast Cancer
De-escalation in Axillary Surgery for Early-stage Breast Cancer
The goal of this clinical trial is to determine if the omission of sentinel lymph node biopsy is safe for early-stage breast cancer patients in our institution (Clinical Hospital Centre Rijeka).
- Trial name
- RIDES (NCT07098507)
- Testing
- sentinel lymph node biopsy, omission of sentinel lymph node biopsy
- Where
- Croatia
- Volunteers
- 620 people
- Sponsor
- Clinical Hospital Center Rijeka
Breast Cancer, Chemotherapeutic Toxicity
AC vs TC in Patients With HR-positive, HER2-negative Early Breast Cancer
Anthracycline-paclitaxel sequential combination therapy is the standard regimen for perioperative chemotherapy in breast cancer. The strategy of perioperative chemotherapy is based on breast cancer subtype, i.e.
- Trial name
- NCT05302336
- Testing
- Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer Female
Radiofrequency Ablation (RFA) in Breast Tumors
To validate the efficacy and safety of the cool-tip ablation method for breast tumors smaller than 2 cm.
- Trial name
- RFA (NCT04389216)
- Testing
- Cool-tip electrode for Radiofrequency Ablation
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Universitari de Bellvitge
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement.
- Conditions
- Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma
- Trial name
- PROFFi (NCT06113016)
- Testing
- Biospecimen Collection, Educational Intervention, Exercise Intervention
- Where
- 6 sites in United States
- Volunteers
- 164 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Early and Locally Advanced Breast Cancer
ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness
The goal of this performance study is to learn if treatment with neoadjuvant endocrine therapy compared to chemotherapy has comparable efficacy, but better quality of life outcomes in endocrine responsive participants with early…
- Trial name
- TEODOR (NCT07084558)
- Testing
- blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived)
- Where
- 14 sites in Austria
- Volunteers
- 350 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Cancer
A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early
Patients with localized primary breast cancer including inflammatory breast cancer suitable for primary medical treatment and/or regional lymph node metastases receive six cycles of chemotherapy with epirubicin and docetaxel.
- Trial name
- PROMIX (NCT00957125)
- Testing
- Epirubicin, Docetaxel, Bevacizumab
- Where
- 6 sites in Sweden
- Volunteers
- 151 people
- Sponsor
- Thomas Hatschek
Breast Cancer, HER2 + Breast Cancer
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
The aim of this study is to evaluate the efficacy and safety of TQB2102 compared to TCbHP in the neoadjuvant treatment of HER2-positive breast cancer.
- Trial name
- NCT07136974
- Testing
- TQB2102, Docetaxel + Carboplatin + Trastuzumab +Pertuzumab
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Henan Cancer Hospital
Early Breast Cancer
Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer
This is a multicenter, open-label, single-arm, one-stage, phase II study to assess the efficacy of a chemotherapy-free pathological complete response (pCR)-guided strategy with trastuzumab and pertuzumab (given as a subcutaneous…
- Trial name
- PHERGAIN-2 (NCT04733118)
- Testing
- Trastuzumab and Pertuzumab (FDC SC) and T-DM1
- Where
- 41 sites in Bulgaria, Germany and 3 more
- Volunteers
- 393 people
- Sponsor
- MedSIR
Breast Cancer
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
This is a prospective, registry trial which will enroll women aged 65 and above with early stage, low risk breast cancer who will be treated with partial mastectomy and intraoperative radiation therapy (IORT).
- Trial name
- NCT03536897
- Testing
- IORT
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Mount Carmel Health System
Breast Cancer
PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer
Non-randomized, open label, multicentric translational research study in women with untreated invasive breast carcinoma eligible for primary surgery (Stage I-IIIA).
- Trial name
- PAMELA (NCT01973660)
- Testing
- Lapatinib, Trastuzumab, Endocrine Therapy
- Where
- 22 sites in Spain
- Volunteers
- 151 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2…
- Trial name
- NCT07054190
- Testing
- Inavolisib, Ribociclib, Letrozole
- Where
- 37 sites in United States, Argentina and 5 more
- Volunteers
- 120 people
- Sponsor
- Hoffmann-La Roche
HER2-negative Breast Cancer, Neoadjuvant Chemotherapy
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
Recent clinical studies showed that breast cancer patients especially for those with lymph node metastasis may benefit from dose-dense chemotherapy, like adriamycin and cyclophosphamide (AC) q2w×4→ paclitaxel (P) q2w×4.
- Trial name
- NCT04576143
- Testing
- Epirubicin, Cyclophosphamid, Docetaxel
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Neoplasms, Solid Tumor
Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia
DNA methylation changes occur early and broadly during carcinogenesis. Methylscape is a rapid assay that detects global DNA methylation patterns in body fluids (blood, urine, and saliva) and may detect a cancer signal and predict…
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Lung Neoplasms
- Trial name
- METHYLSCAPE-CO (NCT07741435)
- Testing
- Methylscape DNA methylation assay
- Where
- Colombia
- Volunteers
- 3,250 people, healthy volunteers welcome
- Sponsor
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Sarcopenia, Paclitaxel Induced Neuropathy
Sarcopenia and Paclitaxel-Induced Neuropathy in Early Stage Breast Cancer (Neuro-Sarc)
This prospective observational study aims to investigate the relationship between sarcopenia and the development of paclitaxel-induced peripheral neuropathy in patients with early-stage breast cancer.
- Conditions
- Sarcopenia, Paclitaxel Induced Neuropathy, Breast Carcinoma
- Trial name
- Neuro-Sarc (NCT06996548)
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Gazi University
Breast Cancer
Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer
The aim of this study is to assess the safety and efficacy of neoadjuvant hormone therapy with letrozole in postmenopausal women with estrogen- and/or progesterone-receptor positive primary breast cancer on tumour regression to…
- Trial name
- NCT00330317
- Testing
- letrozole
- Where
- 20 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
Current guidelines as those from the AGO-Breast commission recommend for neoadjuvant breast cancer patients either a sequence of 4 cycles EC followed by 4 cycles of a taxane or 6 cycles of TAC based on previous large scale…
- Conditions
- Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer
- Trial name
- GeparSepto (NCT01583426)
- Testing
- nab-Paclitaxel, Paclitaxel
- Where
- Germany
- Volunteers
- 1,229 people
- Sponsor
- GBG Forschungs GmbH
Invasive Breast Cancer
Adding Preoperative Radiotherapy Based on Early Treatment Response in Breast Cancer
RAPID-NeoBC is a prospective, multicentre, response-adapted study with a randomized component for adults with operable, nonmetastatic invasive breast cancer receiving guideline-recommended neoadjuvant systemic therapy.
- Trial name
- RAPID-NeoBC (NCT07892508)
- Testing
- Response-adapted preoperative radiotherapy, Guideline-recommended neoadjuvant systemic therapy, Serial contrast-enhanced breast MRI and breast-specific gamma imaging
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer
This proposal is for a Window of Opportunity (WOO) clinical trial using a novel combination of two Health Canada approved agents, cemiplimab (Libtayo) and dupilumab (Dupixent), for off label use in early-stage estrogen receptor…
- Trial name
- NCT05967884
- Testing
- Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer
Percutaneous Cryoablation of Low-risk Early Breast Cancer
Expand the current evidence base regarding percutaneous cryoablation of early-stage, low-risk breast tumors, integrated into the standard therapeutic pathway with well-defined follow-up data, as well as data on quality of life.
- Trial name
- PRECICE (NCT06300125)
- Testing
- Cryoablation
- Where
- Italy
- Volunteers
- 234 people
- Sponsor
- European Institute of Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.